Table 3.
Assessment of cross-resistance with known MV inhibitors
| aPubchem ID (SID) | bEC50 [μM] (MV-AII-5) | cEC50 [μM] (MV-Ibd) | dEC50 [μM] (MV-Alaska) |
|---|---|---|---|
| 846635 | 3.7 ± 0.1 | no activity detected | 2.7 ± 0.2 |
| 852230 | 4.5 ± 0.2 | no activity detected | 3.3 ± 0.1 |
| 4242806 | 2.1 ± 0.1 | ND | 1.4 ± 0.2 |
| 4245209 | 14.3 ± 0.8 | no activity detected | 5.9 ± 1.7 |
| 4256670 | 4.0 ± 0.1 | 26.6 ± 9.3 | 2.2 ± 0.3 |
| 4259333 | 4.3 ± 0.3 | ND | 3.3 ± 0.4 |
| 4261934 | 3.9 ± 0.1 | ND | 2.4 ± 0.5 |
| 4265637 | 4.7 ± 0.3 | no activity detected | 3 ± 0.2 |
| 7973070 | 2.0 ± 0.2 | ND | 0.4 ± 0.1 |
| 7976354 | 1.0 ± 0.1 | ND | 4.6 ± 0.1 |
| 14722514 | 3.6 ± 1.6 | ND | 0.7 ± 0.1 |
| 14723513 | 3.6 ± 0.2 | no activity detected | 3.7 ± 0.1 |
| 14735307 | 5.4 ± 1.6 | ND | 3.3 ± 0.9 |
| 14740150 | no activity detected | ND | 4.4 ± 0.1 |
| 14741996 | 7.7 ± 0.1 | ND | 3.2 ± 0.4 |
| 14743644 | 4.6 ± 0.1 | ND | 2.7 ± 0.5 |
| 17409378 | 1.4 ± 0.3 | ND | 0.7 ± 0.1 |
| 17416393 | 2.9 ± 0.5 | no activity detected | 1.5 ± 0.3 |
| 17433375 | 3.2 ± 0.1 | ND | 3.7 ± 0.2 |
| 17505573 | 1.6 ± 0.1 | no activity detected | 3.8 ± 0.5 |
| 22402685 | 1.6 ± 0.2 | no activity detected | 1.9 ± 0.2 |
| 22404943 | 0.5 ± 0.1 | ND | 0.7 ± 0.1 |
| 22406746 | 2 ± 0.1 | ND | 4.1 ± 0.2 |
| 22407448 | 0.1 | ND | 0.2 ± 0.1 |
| 22407466 | 1.0 | ND | 2.1 ± 0.1 |
| 22408576 | 2.0 ± 0.1 | ND | 2.3 ± 0.4 |
| 22410899 | 3.8 ± 0.3 | ND | 3.9 ± 0.1 |
| 22415156 | 2.4 ± 0.2 | ND | 3.6 ± 0.1 |
| 22415419 | 2.2 ± 0.3 | no activity detected | 4.5 ± 0.9 |
| 22415706 | 4.1 | no activity detected | 6.7 ± 0.3 |
a
shading highlights compound identified in pre-screening as fusion inhibitor candidates
b
MV-Alaska variant adapted to grow in the presence of MV RdRp inhibitor AS-136A (Sun et al. 2007; White et al. 2007); values represent averages of two experiments ± range; highest concentration assessed 37.5 μM
c
MV-Ibd, naturally resistant to MV fusion inhibitor AS-48 (Plemper et al. 2004) values represent averages of two experiments ± range; highest concentration assessed 37.5 μM; only compounds identified as fusion inhibitor candidates were tested against MV-Ibd (ND: not determined)
d
for comparison, EC50 values against MV-Alaska (table 1) are shown